South San Francisco biotech Achaogen Inc.has announced top-line Phase III results with its lead product, plazomicin, an engineered aminoglycoside, that it says puts it in a position potentially to offer a much needed new treatment option for serious multidrug-resistant bacterial infections.
The company believes plazomicin is unique in the way it has been engineered to make it resistant to aminoglycoside-modifying enzymes...






